Thus a personalized therapy approach should take into consideration the following parameters at diagnosis and post the first week of treatment with GCs: (1) the mutational status of NR3C1, including the exact type and the homozygous or heterozygous presence of mutations, as well as NR3C1 cofactors that have been shown to be mutated in ALL, such as CBP; (2) the mutational status of pathways such as NOTCH1 and PTEN/AKT/PI3K; (3) the transcriptional levels and isoforms of NR3C1; (4) levels of LCK, USP7, and USP11; (5) expression of proapoptotic factors. Here, USP7 is linked to acute lymphoblastic leukemia.